MX2021000069A - Composiciones y metodos para tratar la enfermedad intestinal inflamatoria. - Google Patents

Composiciones y metodos para tratar la enfermedad intestinal inflamatoria.

Info

Publication number
MX2021000069A
MX2021000069A MX2021000069A MX2021000069A MX2021000069A MX 2021000069 A MX2021000069 A MX 2021000069A MX 2021000069 A MX2021000069 A MX 2021000069A MX 2021000069 A MX2021000069 A MX 2021000069A MX 2021000069 A MX2021000069 A MX 2021000069A
Authority
MX
Mexico
Prior art keywords
methods
compositions
subject
inflammatory bowel
bowel disease
Prior art date
Application number
MX2021000069A
Other languages
English (en)
Inventor
Whitman Schofield
Original Assignee
Artizan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artizan Biosciences Inc filed Critical Artizan Biosciences Inc
Publication of MX2021000069A publication Critical patent/MX2021000069A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1257—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bacteridaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen composiciones y métodos para tratar enfermedades intestinales inflamatorias en un sujeto que lo necesite. En determinados aspectos, la descripción proporciona métodos para tratar a un sujeto al que se le diagnostica enfermedad del intestino Iiritable (EII), donde el método comprende administrar al sujeto un agente para reducir el número o los efectos patógenos de una cepa de B. fragilis, en donde al sujeto se le diagnostica EII al detectar la presencia de la cepa de B. fragilis o una toxina de B. fragilis en una muestra biológica del paciente.
MX2021000069A 2018-07-03 2019-07-03 Composiciones y metodos para tratar la enfermedad intestinal inflamatoria. MX2021000069A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693798P 2018-07-03 2018-07-03
PCT/US2019/040601 WO2020010254A1 (en) 2018-07-03 2019-07-03 Compositions and methods for treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
MX2021000069A true MX2021000069A (es) 2021-05-31

Family

ID=69059935

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000069A MX2021000069A (es) 2018-07-03 2019-07-03 Composiciones y metodos para tratar la enfermedad intestinal inflamatoria.

Country Status (12)

Country Link
US (1) US20210261651A1 (es)
EP (1) EP3817771A4 (es)
JP (1) JP2021529828A (es)
KR (1) KR20210029217A (es)
CN (1) CN112739376A (es)
AU (1) AU2019297455A1 (es)
BR (1) BR112021000025A2 (es)
CA (1) CA3104402A1 (es)
IL (1) IL279859A (es)
MX (1) MX2021000069A (es)
SG (1) SG11202012774TA (es)
WO (1) WO2020010254A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202227394A (zh) * 2020-09-11 2022-07-16 美商工匠生物科技股份有限公司 細菌毒素之小分子抑制劑
KR102478205B1 (ko) * 2020-09-24 2022-12-15 경희대학교 산학협력단 크론병 환자에서 상부위장관 침범 진단을 위한 정보 제공 방법
CN114409777B (zh) * 2022-01-20 2023-09-01 温玉荣 结直肠癌相关脆弱拟杆菌毒素蛋白激活体的特异性纳米抗体Nb3.27及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
EP2414546A4 (en) * 2009-04-02 2013-03-13 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF CHRONIC INFLAMMATORY INTESTINAL DISEASES AND COLON CANCER
WO2011107481A2 (en) * 2010-03-01 2011-09-09 Institut National De La Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
EP3235506B1 (en) * 2010-07-26 2023-12-06 Qu Biologics Inc. Immunogenic anti-inflammatory compositions
CN105434476B (zh) * 2015-10-29 2019-02-15 广州知易生物科技有限公司 一种脆弱拟杆菌在预防和/或治疗炎症性肠病中的应用

Also Published As

Publication number Publication date
CA3104402A1 (en) 2020-01-09
BR112021000025A2 (pt) 2021-04-06
EP3817771A4 (en) 2022-03-23
JP2021529828A (ja) 2021-11-04
EP3817771A1 (en) 2021-05-12
WO2020010254A1 (en) 2020-01-09
AU2019297455A1 (en) 2021-02-04
US20210261651A1 (en) 2021-08-26
CN112739376A (zh) 2021-04-30
IL279859A (en) 2021-03-01
SG11202012774TA (en) 2021-01-28
KR20210029217A (ko) 2021-03-15

Similar Documents

Publication Publication Date Title
Rainard et al. Knowledge gaps and research priorities in Staphylococcus aureus mastitis control
Windsor Paratuberculosis in sheep and goats
MX2021000069A (es) Composiciones y metodos para tratar la enfermedad intestinal inflamatoria.
Yotsu et al. Revisiting buruli ulcer
Szulc et al. Presence of periodontopathic bacteria DNA in atheromatous plaques from coronary and carotid arteries
Patankar et al. Flagellar motility is a key determinant of the magnitude of the inflammasome response to Pseudomonas aeruginosa
BR112017010268A2 (pt) agente de ligação; composição de diagnóstico; kit de diagnóstico; métodos de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral; para descartar uma infecção bacteriana em um indivíduo; para descartar uma infecção viral em um indivíduo; para considerar uma infecção bacteriana em um indivíduo; para considerar uma infecção viral em um indivíduo; para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo; para fornecer uma recomendação de tratamento para um indivíduo; para fornecer uma recomendação de teste de diagnóstico para um indivíduo; para descartar uma doença infecciosa; para identificação do tipo de infecção; e dispositivo para o diagnóstico de infecções bacterianas
MX2018011480A (es) Metodos de intervencion temprana para prevenir o aminorar toxicidad.
MX2018009738A (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue.
Salo et al. Decorin binding proteins of Borrelia burgdorferi promote arthritis development and joint specific post-treatment DNA persistence in mice
AR084373A1 (es) Composiciones y metodos para la eliminacion de biopeliculas
De Almeida et al. Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244
FR2909099B1 (fr) Methode de diagnostic et de suivi d'une vaginose bacterienne par quantification moleculaire.
MX2021014302A (es) Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
Zhou et al. Methanogen prevalence throughout the gastrointestinal tract of pre-weaned dairy calves
Mulye et al. Delineating the importance of serum opsonins and the bacterial capsule in affecting the uptake and killing of Burkholderia pseudomallei by murine neutrophils and macrophages
Nair et al. Attenuated mutants of Ehrlichia chaffeensis induce protection against wild-type infection challenge in the reservoir host and in an incidental host
Chávez-Galán et al. Low dose BCG infection as a model for macrophage activation maintaining cell viability
Zeinali et al. Clinical and epidemiological features of the genus Malassezia in Iran
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
MX2021010283A (es) Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
FR2968767B1 (fr) Procede et coffret pour le diagnostic in vitro du cancer de la prostate
Chan et al. A framework for assessing the efficacy of antimicrobials in the control of necrotic enteritis in broiler chickens
Lee et al. Burkholderia pseudomallei: an update on disease, virulence and host interaction.
BR112022022045A2 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento